Board approved fundraise via rights issue of Rs1 equity shares to eligible shareholders on a record date to be fixed, subject to approvals. Size, price, ratio, period to be decided later. Extends serial raise-and-dilute funding pattern to a new rights-route after converts and warrants; keeps working-capital and product-spend overhang central while follow-on funding remains pending. Pricing discount, entitlement ratio, size, record date, use of proceeds and timetable undisclosed; dilution and approval execution remain key monitorables.
Kellton Tech Solutions Recommends USD 50 Million FCCB Fund Raise
Kellton Selected To Build AI Claims Platform For U.S. Healthcare Company
Kellton Receives ADB Excellence Award, Targets $5 Million Strategic Account